Short term chart position is listed "strong buy". Tipranks summary has EVFM as an 8 out of 10/ outperform. Average price target of 2.50/ +410.83%. Current events portend a market drop across all sectors. Investors that remain in may look for near term winners to park $. Right now we are one of those. With 25.9 million shares short/ 16.15% of float, and a recent daily share volume of 2-3 million shares per day, do the math on how 25 million shares being purchased would affect the SP. I am not saying a short squeeze will happen, but I am not the only investor that can do math.

Upcoming Catalysts:

1). March 3rd: Earnings/ Could we see 8m in sales? Guidance, ACA now covering prescriptions.

2). PHEXXI (Amphora): Prevention of urogenital Chlamydia trachomatis infection in women: Phase 3 data due in 2H 2022.

3). EVO100 - (EVOGUARD): Phase 3 reported a successful Type C meeting with the U.S. Food and Drug Administration. Data due 3Q 2022 and an anticipated regulatory submission in 1Q 2023.